Invicro Supports the Alzheimer’s Disease Neuroimaging Initiative
11.12.2019 18:37:00 EET | Business Wire | Press release
Invicro LLC, a Konica Minolta Company, today announced funding support for the Alzheimer’s Disease Neuroimaging Initiative (ADNI), and two of their distinguished scientists within the Alzheimer’s biomarkers space, Drs. Roger Gunn and Kenneth Marek, will join the ADNI-Private Partner Scientific Board (PPSB). Invicro is a global provider of imaging biomarkers, core lab services, advanced analytics and software solutions for drug discovery and development.
ADNI is a longitudinal multicenter study designed to develop clinical, imaging, genetic, and biochemical biomarkers for the early detection and tracking of Alzheimer’s disease (AD). ADNI’s mission strives to detect AD at the earliest stage possible (pre-dementia) and identify ways to track the disease’s progression with biomarkers, as well as support advances in AD intervention, prevention, and treatment.
“Invicro is delighted to support ADNI which plays a central role in the development of biomarkers that enable advances in AD intervention, prevention and treatment,” stated Dr. Gunn, EVP of Quantitative Data Sciences for Invicro and Professor of Molecular Neuroimaging at Imperial College London. “We look forward to joining other Industry leaders on the private partner scientific board to contribute to the success of this outstanding initiative.”
Invicro is an industry leader in neuroimaging and the application of PET and MRI imaging for AD, which fully aligns with ADNI’s mission. Having an established pedigree in coordinating worldwide multi-center Phase II and III clinical imaging trials, Invicro provides management and oversight of radiotracer supply along with centralized data management and advanced analysis of imaging endpoints in drug development and clinical research for AD.
“On behalf of Invicro, we are pleased to be part of such an exciting and progressive initiative for the advancement of AD research,” said Dr. Marek, Distinguished Scientist for Invicro. “Invicro’s research and novel biomarkers have been significant for the progression of clinical trials in AD and neurodegenerative disorders.”
The ADNI-PPSB, convened by the Foundation for the National Institutes of Health, serves as a forum for open dialogue as it relates to the project’s progress and new trends in research and development within the field of Alzheimer’s disease. “The FNIH is delighted that Invicro is joining the ADNI-PPSB, which creates a pre-competitive forum where partners can participate in study-related scientific exchanges,” said Joseph Menetski, Ph.D., Associate Vice President, FNIH. “We welcome Invicro’s expertise in neuroimaging that will contribute to ADNI’s goal of defining the progression of Alzheimer’s disease.”
About Invicro
Headquartered in Boston, MA, Invicro was founded in 2008 and today has offices, laboratories and clinics around the world, from coast-to-coast within the United States, to Europe and Asia that support leading pharmaceutical and biotechnology companies and top research universities. Invicro’s multi-disciplinary team provides solutions to help enhance the discovery and development of life-changing drug across all stages of the drug development pipeline (Phase 0-IV), leveraging all imaging modalities within a broad scope of therapeutic areas, including neurology, oncology, cardiology, and pulmonary. Invicro’s quantitative biomarker services, advanced analytics tools, and clinical operational services are backed by their industry-leading software informatics platforms, VivoQuant® and iPACS®.
Invicro is a Konica Minolta company and part of their precision medicine initiative, which aims to accelerate personalized medicine, discover novel therapeutic targets and develop innovative therapeutic technologies for unmet medical needs. Along with their sister company Ambry Genetics, Invicro develops and leverages the latest approaches in quantitative biomarkers including imaging, quantitative pathology and genomics. Visit www.invicro.com for more information
About Konica Minolta
Konica Minolta, Inc. (Konica Minolta) is a global digital technology company with core strengths in imaging and data analysis, optics, materials, and nano-fabrication. Through innovation, Konica Minolta creates products and digital solutions for the betterment of business and society—today and for generations to come. Across its Business Technologies, Healthcare, and Industrial-facing businesses, the company aspires to be an Integral Value Provider that applies the full range of its expertise to offer comprehensive solutions to the customer’s most pressing problems, works with the partners to ensure the solutions are sustainable, anticipates and addresses tomorrow’s issues, and tailors each solution to meet the unique and specific needs of its valued customers. Leveraging these capabilities, Konica Minolta contributes to productivity improvement and workflow change for its customers and provides leading-edge service solutions in the IoT era. Headquartered in Tokyo and with operations in more than 50 countries, Konica Minolta has more than 43,000 employees serving approximately two million customers in over 150 countries. Konica Minolta is listed on the Tokyo Stock Exchange, (TSE4902). For further information, visit: https://www.konicaminolta.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191211005629/en/
Contact information
Amanda Harrell
VP, Global Marketing
media@invicro.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Beacon Acquires Haize Labs to Power AI for the Real Economy17.9.2026 17:30:00 EEST | Press release
Beacon Software (Beacon), the first centralized AI holding company, today announced that it has acquired Haize Labs, an AI reliability company that tests and safeguards AI agents for real-world deployment. The Haize Labs team will join Beacon to form its Applied AI Research Group, with co-founder and CEO Leonard Tang joining as VP of AI Research to lead the AI operating system that is deployed across Beacon’s companies. Beacon believes that the fastest way to bring AI to the traditional economy is through the software businesses that essential industries already use and trust, equipping them with AI infrastructure. Beacon acquires these businesses for long-term growth and connects them to a centralized AI operating system that compounds with each additional acquisition and industry. The addition of the Haize Labs team will strengthen this centralized technology platform, which provides shared engineering, AI, product and go-to-market capabilities to Beacon’s portfolio of 45 software co
TIMELAB Develops OEM/ODM Hair Straightener Reaching 200°C at All Three Measured Points in 15 Seconds17.9.2026 17:00:00 EEST | Press release
TIMELAB Co., Ltd., a Japanese beauty-appliance OEM/ODM provider, has developed a hair straightener for OEM/ODM customization for international hair care brands and professional markets. In testing at 230 V with a 260°C setting, all three measured plate locations reached at least 200°C after 15 seconds. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914187865/en/ Three-Point Plate Testing A European-market development unit with a maximum setting of 260°C was tested at 230 V. Fifteen seconds after power-on, readings at the front, center and rear were 212.5°C, 227.5°C and 200.0°C, respectively. From around 60 seconds onward, temperature differences among the three points narrowed, indicating a stable trend. Precision Temperature Control An NTC sensor inside the metal ceramic heater (MCH) detects temperature. A microcontroller (MCU) reads the signal and adjusts heater output. Upper and lower MCH heaters are controlled indepen
Earnix Brings Agentic AI to the Decisions That Drive Insurance Performance17.9.2026 16:09:00 EEST | Press release
Earnix today announced the introduction of Agent Hub, a curated catalog of insurance-specific AI agents and apps within Earnix AIOS — the AI Orchestration System powering Earnix’s pricing and rating, underwriting, and customer engagement solutions. Agent Hub brings agentic AI directly into these solutions, enabling more intelligent workflows and strengthening the high-stakes decisions that shape pricing, underwriting, customer engagement, growth, and profitability. In an increasingly turbulent insurance environment, the useful life of an insurance decision is getting shorter. Risk and market conditions are changing faster, making growth, profitability, and portfolio performance harder to manage. AI is increasing the speed and scope of what insurers can analyze, recommend, and increasingly act on — but as intelligence moves closer to action, the standard for governance, explainability, and accountability also rises. For insurers, that shift has direct implications for both financial per
Medisca Launches Global Peptide Division17.9.2026 16:07:00 EEST | Press release
Medisca today announced the launch of Medisca Peptides, a dedicated global division focused on expanding access to API-grade peptides and building an integrated peptide platform for pharmaceutical and personalized medicine markets worldwide. As the peptide landscape evolves, Medisca is proactively building the capabilities and infrastructure needed to support API-grade peptides within applicable regulatory frameworks. The launch represents a significant long-term commitment to peptides, including the expansion of Medisca’s portfolio, strategic manufacturing relationships, and the pharmaceutical infrastructure needed to support the category’s growth. It also signals Medisca’s ambition to become a leading force in the next generation of peptide innovation. For Medisca, the opportunity is familiar. More than 35 years ago, the company was founded to help close the gap between the pharmaceutical standards compounders needed and the quality ingredients they could readily access. Today, as pe
Elliptic Launches Its Decode Agent to Answer On-Chain Risk Questions and Shows Its Work17.9.2026 16:00:00 EEST | Press release
Elliptic, the global leader in on-chain risk, today launched Decode, an AI agent built on Elliptic’s intelligence platform. The Decode agent answers natural-language questions about cryptoasset addresses and their exposure in seconds, and returns the evidence behind every answer. Compliance and investigations teams need answers to questions nobody planned for. Getting them out of the data is now a specialist skill, so the questions wait for someone who has it, or go unasked. Meanwhile illicit actors move at machine speed, and agents are starting to sit on both sides of a payment. General-purpose AI assistants can produce an answer. They cannot show where it came from. A fluent response with nothing behind it cannot be put in front of a second-line reviewer, an auditor, or a regulator. “The market is full of AI that asks to be trusted. That is not good enough when someone asks how you reached a decision,” said Jackson Hull, CTO at Elliptic. “We published the Elliptic Standard last week
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom